Final data from the Phase 2b MUIR study of the ApoC3 hepatocyte-targeted siRNA, plozasiran, presented at the congress and simultaneously published in the New England Journal of Medicine, have confirmed durable reductions in ApoC3 and TG up to 48 weeks of treatment in patients (n=353) with mixed dyslipidaemia including elevated TG.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
